CL2007002766A1 - Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par - Google Patents

Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par

Info

Publication number
CL2007002766A1
CL2007002766A1 CL200702766A CL2007002766A CL2007002766A1 CL 2007002766 A1 CL2007002766 A1 CL 2007002766A1 CL 200702766 A CL200702766 A CL 200702766A CL 2007002766 A CL2007002766 A CL 2007002766A CL 2007002766 A1 CL2007002766 A1 CL 2007002766A1
Authority
CL
Chile
Prior art keywords
composition
granulum
pyrimidil
benzamide
capsule
Prior art date
Application number
CL200702766A
Other languages
English (en)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2007002766A1 publication Critical patent/CL2007002766A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL200702766A 2006-09-27 2007-09-26 Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par CL2007002766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt

Publications (1)

Publication Number Publication Date
CL2007002766A1 true CL2007002766A1 (es) 2008-08-08

Family

ID=37684496

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702766A CL2007002766A1 (es) 2006-09-27 2007-09-26 Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par

Country Status (35)

Country Link
US (2) US8293756B2 (es)
EP (4) EP1923053A1 (es)
JP (2) JP5567340B2 (es)
KR (2) KR20090076931A (es)
CN (2) CN104306350A (es)
AR (1) AR062980A1 (es)
AU (1) AU2007301977B2 (es)
BR (1) BRPI0719438B1 (es)
CA (1) CA2662571C (es)
CL (1) CL2007002766A1 (es)
CO (1) CO6160288A2 (es)
CY (2) CY1117021T1 (es)
DK (2) DK2068839T3 (es)
ES (3) ES2957912T3 (es)
FI (2) FI3984528T3 (es)
HK (1) HK1133193A1 (es)
HR (2) HRP20230753T3 (es)
HU (2) HUE028204T2 (es)
IL (1) IL197496A (es)
JO (1) JO3757B1 (es)
LT (1) LT3984528T (es)
MA (1) MA30807B1 (es)
MX (1) MX2009003184A (es)
MY (1) MY148237A (es)
NO (2) NO347404B1 (es)
NZ (1) NZ575317A (es)
PE (2) PE20081379A1 (es)
PL (2) PL2068839T5 (es)
PT (2) PT3984528T (es)
RU (1) RU2469707C2 (es)
SI (2) SI3984528T1 (es)
TN (1) TN2009000093A1 (es)
TW (3) TW201418245A (es)
WO (1) WO2008037716A2 (es)
ZA (1) ZA200901511B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
AU2010299756A1 (en) 2009-09-28 2012-04-19 Medizinische Universitat Wien PDGFRbeta inhibitors for use in the treatment of T-cell lymphoma
RU2012120901A (ru) * 2009-10-23 2013-12-10 Новартис Аг Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
AR088844A1 (es) * 2011-11-14 2014-07-10 Novartis Ag Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
IN2014DN10801A (es) 2012-07-11 2015-09-04 Novartis Ag
WO2014174496A1 (en) 2013-04-25 2014-10-30 Ranbaxy Laboratories Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2016024289A2 (en) 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd Novel salts of nilotinib and polymorphs thereof
WO2016033304A1 (en) * 2014-08-28 2016-03-03 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
AU2017232868B2 (en) * 2016-03-17 2021-07-22 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
AU4491200A (en) 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
US20020048610A1 (en) 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
WO2003103637A2 (en) * 2002-01-10 2003-12-18 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1565258B1 (en) * 2002-11-26 2011-12-14 Universiteit Gent Process and apparatus for continuous wet granulation of powder material
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
WO2005011635A2 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
EP1776102A1 (en) 2004-07-28 2007-04-25 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
CA2580529A1 (en) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Fine particle-containing composition and manufacturing method therefor
EP1830822A1 (en) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
KR20130100371A (ko) * 2005-01-28 2013-09-10 노파르티스 아게 Ｔｉｅ-2 키나제 활성의 조절에 반응하는 질환의 치료를 위한 피리미딜아미노벤즈아미드의 용도
US20080207658A1 (en) * 2005-02-25 2008-08-28 Manley Paul W Pharmaceutical Combination of Bcr-Abl and Raf Inhibitors
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Also Published As

Publication number Publication date
EP3984528A1 (en) 2022-04-20
EP1923053A1 (en) 2008-05-21
AU2007301977B2 (en) 2011-09-08
CA2662571A1 (en) 2008-04-03
SI2068839T1 (sl) 2016-02-29
HK1133193A1 (en) 2010-03-19
EP2068839A2 (en) 2009-06-17
PE20081379A1 (es) 2008-11-27
JO3757B1 (ar) 2021-01-31
AR062980A1 (es) 2008-12-17
CN101516344A (zh) 2009-08-26
CO6160288A2 (es) 2010-05-20
JP5567340B2 (ja) 2014-08-06
CY1126116T1 (el) 2023-11-15
KR20140121903A (ko) 2014-10-16
SI3984528T1 (sl) 2023-09-29
JP2014065715A (ja) 2014-04-17
FI2068839T4 (fi) 2023-01-31
US8501760B2 (en) 2013-08-06
PE20120626A1 (es) 2012-06-07
TW200821298A (en) 2008-05-16
US20100087463A1 (en) 2010-04-08
EP3984528B1 (en) 2023-07-05
ES2556625T3 (es) 2016-01-19
NZ575317A (en) 2011-12-22
EP2068839B2 (en) 2022-10-12
PL2068839T3 (pl) 2016-06-30
RU2469707C2 (ru) 2012-12-20
LT3984528T (lt) 2023-08-10
BRPI0719438A2 (pt) 2013-12-10
RU2009115782A (ru) 2010-11-10
ES2951547T3 (es) 2023-10-23
PT2068839E (pt) 2015-12-30
MY148237A (en) 2013-03-29
ES2556625T5 (es) 2023-03-02
TN2009000093A1 (en) 2010-08-19
MA30807B1 (fr) 2009-10-01
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
FI3984528T3 (fi) 2023-07-27
EP2068839B1 (en) 2015-09-23
PL2068839T5 (pl) 2023-01-30
SI2068839T2 (sl) 2023-01-31
DK3984528T3 (da) 2023-07-31
TW201418245A (zh) 2014-05-16
AU2007301977A1 (en) 2008-04-03
CY1117021T1 (el) 2017-04-05
MX2009003184A (es) 2009-04-03
ES2957912T3 (es) 2024-01-29
ZA200901511B (en) 2010-02-24
KR101598747B1 (ko) 2016-03-02
TWI540128B (zh) 2016-07-01
NO346639B1 (no) 2022-11-07
NO20220946A1 (no) 2009-04-24
HRP20230753T3 (hr) 2023-10-27
JP2010504942A (ja) 2010-02-18
WO2008037716A3 (en) 2008-07-17
EP3009128A1 (en) 2016-04-20
US8293756B2 (en) 2012-10-23
IL197496A0 (en) 2009-12-24
CN104306350A (zh) 2015-01-28
NO20091501L (no) 2009-04-24
KR20090076931A (ko) 2009-07-13
HUE028204T2 (en) 2016-12-28
PT3984528T (pt) 2023-08-07
CA2662571C (en) 2016-09-27
IL197496A (en) 2016-04-21
DK2068839T3 (da) 2016-01-11
BRPI0719438B1 (pt) 2022-04-19
EP3009128B1 (en) 2023-07-05
PL3984528T3 (pl) 2023-08-28
HRP20151383T1 (hr) 2016-01-15
HRP20151383T4 (hr) 2023-03-03
HUE063083T2 (hu) 2023-12-28
US20130023549A1 (en) 2013-01-24
NO347404B1 (no) 2023-10-16
TWI428333B (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
CL2007002766A1 (es) Composicion farmaceutica en forma de capsula que comprende un granulo con un compuesto derivado de pirimidil-amino-benzamida en mezcla intima con al menos un excipiente farmaceuticamente aceptable; metodo de preparacion de dicha composicion, util par
WO2010146179A3 (en) Solid pharmaceutical composition comprising rivaroxaban
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
IL195174A0 (en) Percutaneous absorption preparations of antidementia drugs
IL193727A0 (en) Dosage forms for administering combinations of drugs
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CO6400186A2 (es) Tabletas de acetato de ulipristal
ECSP088980A (es) Composicion farmacéutica que comprende amlodipina y losartán
MX2010007083A (es) Combinacion anti-retroviral.
EA200970449A1 (ru) Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность
ECSP099536A (es) Métodos y formulaciones para biodisponibilidad mejorada de antiprogestinas
HK1134902A1 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2009078034A3 (en) Orally disintegrating tablets of ropinirole hydrochloride
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
PL2071917T3 (pl) System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2009132082A3 (en) Immunogenic compositions containing ceramide and methods of use thereof
DK1853296T3 (da) Anvendelse af et cyklisk undekapeptid til fremstilling af et lægemiddel indgift ved myokardiale iskæmiepisoder
WO2007110765A3 (en) Processes for the preparation of octreotide
BRPI0813658A2 (pt) composto, medicamento, composição farmacêutica, preparação farmacêutica combinada, usos de um composto e de uma preparação combinada, e, processo para a preparação de composto.
WO2008037502A3 (en) Olanzapine pharmaceutical composition with anhydrous lactose
EP1948199A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS